This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Assessment for advanced liver fibrosis in people with NAFLD

Authoring team

Assessment for advanced liver fibrosis in people with NAFLD

Identifying people with advanced liver fifibrosis

  • testing should be offered for advanced liver fibrosis to people with NAFLD
  • consider using the enhanced liver fibrosis (ELF) test in people who have been diagnosed with NAFLD to test for advanced liver fibrosis
  • do not use routine liver blood tests to assess for advanced liver fibrosis in people with NAFLD

  • diagnose people with advanced liver fibrosis if they have:
    • an ELF score of 10.51 or above
    • and NAFLD

  • refer adults and young people diagnosed with advanced liver fibrosis to a relevant specialist in hepatology

  • if an ELF score below 10.51 then:
    • explain that are unlikely to have advanced liver fibrosis
    • reassessment for advanced liver fibrosis every 3 years for adults and every 2 years for children and young people is sufficient for regular monitoring
    • no interim tests are needed
  • consider using ELF for retesting people with advanced liver fibrosis

Extra-hepatic conditions

  • NAFLD is a risk factor for type 2 diabetes, hypertension and chronic kidney disease
  • in people with type 2 diabetes, NAFLD is a risk factor for atrial fibrillation, myocardial infarction, ischaemic stroke and death from cardiovascular causes

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.